Spondyloarthritis

Danielle R., 27, an electrician, needs her first biologic for axial spondyloarthritis and plans to conceive in eighteen months. TNF and IL-17 inhibitors are guideline-equivalent in general — the disagreement is whether her specific conception timeline should be the thing that actually picks the drug.

Marguerite T., 58, a retired postal worker, has axial spondyloarthritis and ulcerative colitis that's been silent for eighteen years. The 2025 guideline lifted the old absolute ban on IL-17 inhibitors in her situation — the disagreement is whether that lift applies equally to both drugs in the class, or only to the one actually studied.

Walter K., 54, a long-haul trucker, wants an oral drug over an injectable for his ankylosing spondylitis. JAK inhibitors are guideline-recommended for axSpA generally — the disagreement is whether that recommendation still holds once his own cardiovascular risk factor is weighed against it specifically.

Aisha B., 24, a graduate student back from fieldwork in a high-tuberculosis region, has a positive latent TB test delaying her first biologic for axial spondyloarthritis. Reaching for sulfasalazine as a bridge sounds reasonable — the disagreement is whether the new guideline's restriction to peripheral disease rules that out for a patient with none.

Sofia M., 31, a kindergarten teacher in three years of remission, wants to taper her biologic before trying for a second child. The evidence supports tapering in general — the disagreement is what to do when the same patient fits nearly every known predictor of a taper failing.

Desmond O., 39, a chef on his feet twelve hours a day, had eight good months on etanercept before a slow fade began. Whether that counts as primary or secondary failure decides his next drug — and a 2025 trial has just complicated which answer the room can still rely on.

Helena F., 45, a high school art teacher, has psoriatic arthritis that improved only partially on adalimumab. Four mechanistically distinct drug classes are all guideline-supported for exactly her situation — the disagreement is which of her own disease features should actually break the tie.

Julian P., 36, a new father working ten-hour shifts on a concrete warehouse floor, needs his first biologic for psoriatic arthritis. His Crohn's disease rules out one class outright — the disagreement is which of the two mechanisms actually left standing fits him better.

Carmen L., 42, a research librarian, has psoriasis fully controlled on an IL-23 inhibitor — and now a new diagnosis of axial psoriatic arthritis, a domain where the current guideline specifically excludes that exact drug class. The disagreement is whether to keep the drug that's already working for her skin or switch to the one her spine actually needs.

Otis G., 51, a hardware store owner, has dactylitis and Achilles enthesitis persisting despite adalimumab. Four mechanisms are all guideline-supported for exactly his domain of disease — the disagreement is whether the real tie-breaker should be a drug he's already familiar with rather than a clinical distinction.

Naomi R., 29, six months into a line-cook job she loves, has active Crohn's disease and a knee arthritis that just started. The drug class with the strongest joint-specific evidence is the same one shown, in a real trial, to make her exact bowel disease worse.

Tobias H., 33, a wrestling coach, has a back-pain history that fits axial spondyloarthritis in every way a history can. His MRI and CRP don't clear the objective-inflammation bar that biologic eligibility is actually built on.

Bridget A., 40, a wedding and portrait photographer whose career depends on her eyes, has mild ankylosing spondylitis and much more serious recurrent anterior uveitis. The two most commonly reached-for TNF inhibitors have opposite track records for the complication that's actually threatening her.